SpringerLink
Log in

Clinicopathologic Features and Treatment Outcomes in Cronkhite–Canada Syndrome: Support for Autoimmunity

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background and Aims

Cronkhite–Canada syndrome (CCS) is a noninherited condition, associated with high morbidity, and characterized by gastrointestinal hamartomatous polyposis, alopecia, onychodystrophy, hyperpigmentation, and diarrhea. All features may respond to immunosuppressive therapy, but little is known about the etiology. An autoimmune origin has been suggested but not proved. From a retrospectively selected cohort, we evaluated clinicopathologic features, including immunostaining for IgG4 (an antibody associated with autoimmunity), and therapeutic outcomes in a cohort of CCS patients to provide further insights into this disease.

Methods

Cases included 14 consecutive CCS patients seen at the Mayo Clinic on whom tissue and follow-up were available. All histology was reviewed by an expert gastrointestinal pathologist. Immunostaining for IgG4 was performed on 42 polyps from CCS cases and on control tissues, including 46 histologically similar hamartomas [from juvenile polyposis syndrome (JPS)] and 20 normal mucosae (six stomach, three small bowel, and 11 colon). Clinical features and treatment outcomes were descriptive.

Results

All CCS cases had both upper and lower gastrointestinal polyps; most had typical dermatologic features of alopecia, hyperpigmentation, and onychodystrophy; and most had evidence of protein-losing enteropathy. Ten patients (71%) had adenomatous polyps and 2 (14%) had colorectal cancer. IgG4 immunostaining was positive (>5 cells/HPF) in 52% of CCS polyps compared to 12% of JPS polyps (P = 0.001); IgG4 staining was negative in all other control tissues. Of 11 CCS patients treated with oral corticosteroids, 91% achieved remission. Relapse was common with steroid tapering. Five patients who initially responded to corticosteroids were maintained in remission on azathioprine (2 mg/kg/day) with no relapse after a median of 4.5 years.

Conclusions

Immunostaining for the autoimmune-related IgG4 antibody is significantly increased in CCS polyps compared to disease and normal control tissues. Furthermore, immunosuppression by corticosteroids or long-term azathioprine may eradicate or lessen manifestations of CCS. These histologic findings and treatment responses are consistent with an autoimmune mechanism underlying CCS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

CCS:

Cronkhite–Canada syndrome

JPS:

Juvenile polyposis syndrome

AIP:

Autoimmune pancreatitis

References

  1. Cronkhite L, Canada W. Generalized gastrointestinal polyposis: An unusual syndrome of polyposis, pigmentation, alopecia, and onychotrophia. N Engl J Med. 1955;252:1011–1015.

    Article  PubMed  Google Scholar 

  2. Bacher T, Schonekas H, Steurer KT, Wunsch PH. The Cronkhite-Canada Syndrome. A rare differential diagnosis of generalized gastrointestinal polyposis. Dtsch Med Wochenschr. 1997;122:676–681.

    Article  PubMed  CAS  Google Scholar 

  3. Burnell RH. Cronkhite-Canada syndrome. Med J Aust. 1976;1:347–348.

    PubMed  CAS  Google Scholar 

  4. Cotterill JA, Hughes JP, Day JL, Paulley JW, Turk E. The Cronkhite-Canada syndrome. Postgrad Med J. 1973;49:268–273.

    Article  PubMed  CAS  Google Scholar 

  5. Daniel ES, Ludwig SL, Lewin KJ, Ruprecht RM, Rajacich GM, Schwabe AD. The Cronkhite-Canada syndrome. An analysis of clinical and pathologic features and therapy in 55 patients. Medicine. 1982;61:293–309.

    Article  PubMed  CAS  Google Scholar 

  6. Freeman K, Anthony PP, Miller DS, Warin AP. Cronkhite-Canada syndrome. J R Soc Med. 1984;77:4–5.

    PubMed  Google Scholar 

  7. Goto A. Cronkhite-Canada syndrome: Epidemiological study of 110 cases reported in Japan. Nihon Geka Hokan. 1995;64:3–14.

    PubMed  CAS  Google Scholar 

  8. Nishiki M, Takasugi S, Kanao M, Okumichi T, Tamura T, Ezaki H. Cronkhite-Canada syndrome. A case report and analytical review of 37 other cases reported in Japan. Hiroshima J Med Sci. 1984;33:607–614.

    PubMed  CAS  Google Scholar 

  9. Lipper S, Kahn LB. Superficial cystic gastritis with alopecia. A forme fruste of the Cronkhite-Canada syndrome. Arch Pathol Lab Med. 1977;101:432–436.

    PubMed  CAS  Google Scholar 

  10. Boardman L. Hereditable colon cancer syndromes: Recognition and prevention management. Gastroenterol Clin North Am. 2002;31:1107–1131.

    Article  PubMed  Google Scholar 

  11. Schreibman I, Baker M, Amos C, McGarrity T. The hamartomatous polyposis syndromes: A clinical and molecular review. Am J Gastroenterol. 2005;100:476–490.

    Article  PubMed  Google Scholar 

  12. Burke AP, Sobin LH. The pathology of Cronkhite-Canada polyps. A comparison to juvenile polyposis. Am J Surg Pathol. 1989;13:940–946.

    Article  PubMed  CAS  Google Scholar 

  13. Chadalavada R, Brown DK, Walker AN, Sedghi S. Cronkhite-Canada syndrome: Sustained remission after corticosteroid treatment. Am J Gastroenterol. 2003;98:1444–1446.

    Article  PubMed  Google Scholar 

  14. Doyle T, Jarvis R. Reversal of changes in Cronkhite-Canada syndrome. Australas Radiol. 1984;28:19–22.

    Article  PubMed  CAS  Google Scholar 

  15. Goto A. Cronkhite-Canada syndrome: Observations about treatment, course and prognosis of 123 cases reported in Japan. Nihon Geka Hokan. 1988;57:427–433.

    PubMed  CAS  Google Scholar 

  16. Lin HJ, Tsai YT, Lee SD, et al. The Cronkhite-Canada syndrome with a focus on immunity and infection, report of a case. J Clin Gastroenterol. 1987;9:560–570.

    Article  Google Scholar 

  17. Takahashi H, Yamamoto M, Suzuki C, et al. The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity. Autoimmun Rev. 2010;9:591–594.

    Article  PubMed  CAS  Google Scholar 

  18. Nishimori I, Otsuki M. Autoimmune pancreatitis and IgG4-associated sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2009;23:11–23.

    Article  PubMed  CAS  Google Scholar 

  19. Kim M-W, Moon S-H, Kamisawa T. Major duodenal papilla in autoimmune pancreatitis. Dig Surg. 2010;27:110–114.

    Article  PubMed  Google Scholar 

  20. Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–738.

    Article  PubMed  CAS  Google Scholar 

  21. Moon S-H, Kim M-H, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008;57:1704–1712.

    Article  PubMed  CAS  Google Scholar 

  22. Hamano H, Kawa S, Uehara T, et al. Immunoglobulin G4-related lymphoplasmocytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: Part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc. 2005;62:152–157.

    Article  PubMed  Google Scholar 

  23. Awazuhara H, Kawai H, Maruchi N. Major allergens in soybean and clinical significance of IgG4 antibodies investigated by IgE- and IgG4-immunoblotting with sera from soybean-sensitive patients. Clin Exp Allergy. 1997;27:325–332.

    Article  PubMed  CAS  Google Scholar 

  24. el Rafei A, Peters SM, Harris N, Bellanti JA. Diagnostic value of IgG4 measurements in patients with food allergy. Ann Allergy. 1989;62:94–99.

    PubMed  CAS  Google Scholar 

  25. Zar S, Mincher L, Benson MJ, Kumar D. Food-specific IgG4 antibody-guided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome. Scand J Gastroenterol. 2005;40:800–807.

    Article  PubMed  Google Scholar 

  26. Nagata J, Kijima H, Hasumi K, Suzuki T, Shirai T, Mine T. Adenocarcinoma and multiple adenomas of the large intestine, associated with Cronkhite-Canada syndrome. Dig Liver Dis. 2003;35:434–438.

    Article  PubMed  CAS  Google Scholar 

  27. Nonomura A, Ohta G, Ibata T, Shinozaki K, Nishino T. Cronkhite-Canada syndrome associated with sigmoid cancer case report and review of 54 cases with the syndrome. Acta Pathol Jpn. 1980;30:825–845.

    PubMed  CAS  Google Scholar 

  28. Katayama Y, Kimura M, Konn M. Cronkhite-Canada syndrome associated with a rectal cancer and adenomatous changes in colonic polyps. Am J Surg Pathol. 1985;9:65–71.

    Article  PubMed  CAS  Google Scholar 

  29. Malhotra R, Sheffield A. Cronkhite-Canada syndrome associated with colon carcinoma and adenomatous changes in C–C polyps. Am J Gastroenterol. 1988;83:772–776.

    PubMed  CAS  Google Scholar 

  30. Jain A, Nanda S, Chakraborty P, et al. Cronkhite-Canada syndrome with adenomatous and carcinomatous transformation of colonic polyp. Indian J Gastroenterol. 2003;22:189–190.

    PubMed  Google Scholar 

  31. Kaneko Y, Kato H, Tachimori Y, et al. Triple carcinomas in Cronkhite-Canada syndrome. Jpn J Clin Oncol. 1991;21:194–202.

    PubMed  CAS  Google Scholar 

  32. Murai N, Fukuzaki T, Nakamura T, et al. Cronkhite-Canada syndrome associated with colon cancer: Report of a case. Surg Today. 1993;23:825–829.

    Article  PubMed  CAS  Google Scholar 

  33. Watanabe T, Kudo M, Shirane H, et al. Cronkhite-Canada syndrome associated with triple gastric cancers: A case report. Gastrointest Endosc. 1999;50:688–691.

    Article  PubMed  CAS  Google Scholar 

  34. Yamaguchi K, Ogata Y, Akagi Y, et al. Cronkhite-Canada syndrome associated with advanced rectal cancer treated by a subtotal colectomy: Report of a case. Surg Today. 2001;31:521–526.

    Article  PubMed  CAS  Google Scholar 

  35. Zugel NP, Hehl JA, Jechart G, Tannapfel A, Wienbeck M, Witte J. Colorectal carcinoma in Cronkhite-Canada syndrome. Z Gastroenterol. 2001;39:365–367.

    Article  PubMed  CAS  Google Scholar 

  36. Radha Krishna Y, Ghoshal UC, Pandey R, et al. Cronkhite-Canada syndrome with Adenomatous polyposis. J Postgrad Med. 2008;54:144–146.

    Article  Google Scholar 

  37. Nakatsubo N, Wakasa R, Kiyosaki K, et al. Cronkhite-Canada syndrome associated with carcinoma of the sigmoid colon: Report of a Case. Jpn J Surg. 1997;27:345–348.

    Article  CAS  Google Scholar 

  38. Yashiro M, Kobayashi H, Kubo N, Nishiguchi Y, Wakasa K, Hirakawa K. Cronkhite-Canada syndrome containing colon cancer and serrated adenoma lesions. Digestion. 2004;69:57–62.

    Article  PubMed  Google Scholar 

  39. Misra SP, Misra V, Dwivedi M, Singh PA, Gupta SC. Cronkhite–Canada syndrome without colonic polyps. Endoscopy. 1997;29:333.

    Article  PubMed  CAS  Google Scholar 

  40. Naitoh H, Eimoto T, Kamachi H. An autopsy case of Cronkhite-Canada syndrome develo** after hemicolectomy for colonic cancer. Gan No Rinsho. 1986;32:1619–1624.

    PubMed  CAS  Google Scholar 

  41. van der Zee JS, van Swieten P, Aalberse RC. Inhibition of complement activation by IgG4 antibodies. Clin Exp Immunol. 1986;64:415–422.

    PubMed  Google Scholar 

  42. Takeuchi Y, Yoshikawa M, Tsukamoto N, et al. Cronkhite-Canada syndrome with colon cancer, portal vein thrombosis, high titer of antinuclear antibodies, and membranous glomerulonephritis. J Gastroenterol. 2003;38:791–795.

    Article  PubMed  Google Scholar 

  43. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–1507.

    Article  PubMed  CAS  Google Scholar 

  44. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: The Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4:1010–1016.

    Article  PubMed  Google Scholar 

  45. Pannala R, Chari ST. Corticosteroid treatment for autoimmune pancreatitis. Gut. 2009;58:1438–1439.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

No conflicts of interest exist.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA

    Seth Sweetser, David A. Ahlquist, Neal K. Osborn, Suresh T. Chari & Lisa A. Boardman

  2. Division of Anatomic Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA

    Schuyler O. Sanderson & Thomas C. Smyrk

Authors
  1. Seth Sweetser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Ahlquist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neal K. Osborn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Schuyler O. Sanderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas C. Smyrk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suresh T. Chari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lisa A. Boardman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seth Sweetser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sweetser, S., Ahlquist, D.A., Osborn, N.K. et al. Clinicopathologic Features and Treatment Outcomes in Cronkhite–Canada Syndrome: Support for Autoimmunity. Dig Dis Sci 57, 496–502 (2012). https://doi.org/10.1007/s10620-011-1874-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-011-1874-9

Keywords

Search

Navigation